IRIS
CONTE, BENEDETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 156
EU - Europa 6
NA - Nord America 4
Totale 166
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 81
HK - Hong Kong 75
IT - Italia 4
US - Stati Uniti d'America 3
CA - Canada 1
DE - Germania 1
LT - Lituania 1
Totale 166
Salva come PNG Salva come JPEG
Città #
Hong Kong 75
Singapore 55
Milan 2
Sarno 2
Nuremberg 1
Ottawa 1
Seattle 1
Totale 137
Salva come PNG Salva come JPEG
Nome #
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial 9
Frequency and spectrum of PIK3CA somatic mutations in breast cancer 8
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 8
Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial 7
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 7
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study 7
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 6
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 6
Breast Cancer Surgery in the COVID-19 Pandemic: Validation of a Preventive Program for Patients and Health Care Workers 6
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 6
De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence 6
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer 6
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 6
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis 6
SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials 6
Update on the management of breast cancer during pregnancy 5
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy 5
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial 5
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 5
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 5
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis 5
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients 5
Management of young women with early breast cancer 5
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis 5
Luteinizing hormone-releasing hormone analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor-positive breast cancer 4
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 4
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer 4
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 4
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 4
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 4
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy 4
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review 4
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study 4
Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer 4
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. 4
Management of young women with early breast cancer 4
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 4
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study 3
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 3
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy 2
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 2
Totale 207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.179
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.179
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025207 0 0 0 87 28 90 2 0 0 0 0 0
Totale 207